{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(2)"],"submitter":["Leroux-Roels G"],"pubmed_abstract":["<h4>Unlabelled</h4>Mucosal antibodies harboring various antiviral activities may best protect mucosal surfaces against early HIV-1 entry at mucosal sites and they should be ideally induced by prophylactic HIV-1 vaccines for optimal prevention of sexually transmitted HIV-1. A phase I, double-blind, randomized, placebo-controlled trial was conducted in twenty-four healthy HIV-uninfected young women. The study objectives were to assess the safety, tolerability and immunogenicity of virosomes harboring surface HIV-1 gp41-derived P1 lipidated peptides (MYM-V101). Participants received placebo or MYM-V101 vaccine at 10 μg/dose or 50 μg/dose intramuscularly at week 0 and 8, and intranasally at week 16 and 24. MYM-V101 was safe and well-tolerated at both doses administered by the intramuscular and"],"journal":["PloS one"],"pagination":["e55438"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3577797"],"repository":["biostudies-literature"],"pubmed_title":["Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes."],"pmcid":["PMC3577797"],"pubmed_authors":["Clement F","van den Dobbelsteen M","Leroux-Roels G","Bomsel M","Lopalco L","Fleury S","van Engelenburg F","Adler M","Amacker M","Chalifour A","Maes C"],"additional_accession":[]},"is_claimable":false,"name":"Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.","description":"<h4>Unlabelled</h4>Mucosal antibodies harboring various antiviral activities may best protect mucosal surfaces against early HIV-1 entry at mucosal sites and they should be ideally induced by prophylactic HIV-1 vaccines for optimal prevention of sexually transmitted HIV-1. A phase I, double-blind, randomized, placebo-controlled trial was conducted in twenty-four healthy HIV-uninfected young women. The study objectives were to assess the safety, tolerability and immunogenicity of virosomes harboring surface HIV-1 gp41-derived P1 lipidated peptides (MYM-V101). Participants received placebo or MYM-V101 vaccine at 10 μg/dose or 50 μg/dose intramuscularly at week 0 and 8, and intranasally at week 16 and 24. MYM-V101 was safe and well-tolerated at both doses administered by the intramuscular and","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013","modification":"2026-05-03T15:09:21.931Z","creation":"2026-04-07T19:20:25.848Z"},"accession":"S-EPMC3577797","cross_references":{"pubmed":["23437055"],"doi":["10.1371/journal.pone.0055438"]}}